Zhongsheng Pharma Stock Code: 002317 Announcement No.: 2026-017
Guangdong Zhongsheng Pharmaceutical Co., Ltd. Announcement on Wholly-Owned Subsidiary Obtaining Approval for Fumaric Acid Clemastine API Listing Application
The Company and the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed herein, and that there are no false records, misleading statements, or material omissions.
Guangdong Zhongsheng Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company")'s wholly-owned subsidiary, Guangdong Xianqiang Pharmaceutical Co., Ltd., recently received the "Approval Notification for Listing Application of Chemical API" for Fumaric Acid Clemastine issued by the National Medical Products Administration. The relevant situation is hereby announced as follows:
I. Main Content of the "Approval Notification for Listing Application of Chemical API" Registration Number: Y20240001306 Notification Number: 2026YS00305 Chemical API Name: Fumaric Acid Clemastine Application Matter: Listing application for domestically produced chemical API Manufacturing Enterprise: Name: Guangdong Xianqiang Pharmaceutical Co., Ltd., Address: No. 6, Industrial Avenue, Guangzhou Economic and Technological Development Zone, Guangzhou Approval Conclusion: In accordance with the "Drug Administration Law of the People's Republic of China" and relevant regulations, after review, the product meets the relevant requirements for drug registration, and its production is approved.